TABLE 1.
Patient and Tumor Characteristics
| Variable | Total Cohort |
|---|---|
| (N = 706) | |
| Age, median (IQR) | 66 (57, 72) |
| Sex, n (%) | |
| Male | 488 (69.1) |
| Female | 218 (30.9) |
| BMI, n (%) | |
| Normal (18.5–24.9) | 430 (60.9) |
| Underweight (<18.5) | 78 (11.0) |
| Overweight (25.0–29.9) | 170 (24.1) |
| Obese (≥30.0) | 28 (4.0) |
| ASA score, n (%) | |
| I | 209 (29.6) |
| II | 444 (62.9) |
| III | 52 (7.4) |
| IV | 1 (0.1) |
| Neoadjuvant therapy, n (%) | |
| None | 392 (55.5) |
| NACRT | 106 (15.0) |
| NAC | 188 (26.6) |
| RT | 8 (1.1) |
| TNT | 12 (1.7) |
| Distance from AV (cm), median (IQR) | 4.0 (3.0, 5.0) |
| Tumor location, n (%) | |
| Anterior/circumferential | 398 (56.4) |
| Not anterior | 308 (43.6) |
| cT*, n (%) | |
| 0/is | 1 (0.3) |
| 1 | 106 (15.0) |
| 2 | 128 (18.1) |
| 3 | 334 (47.3) |
| 4a | 59 (8.4) |
| 4b | 75 (10.6) |
| cN*, n (%) | |
| 0 | 381 (54.0) |
| 1 | 198 (28.0) |
| 2 | 127 (18.0) |
| cM*, n (%) | |
| 0 | 610 (86.4) |
| 1 | 96 (13.6) |
| cStage*, n (%) | |
| I | 205 (29.0) |
| II | 157 (22.2) |
| III | 253 (35.8) |
| IV | 91 (12.9) |
| CEA, median (IQR) | 3.7 (2.2, 7.4) |
| Missing, n (%) | 1 (0.1) |
| CA19-9, median (IQR) | 10.7 (6.0, 21.0) |
| Missing, n (%) | 3 (0.4) |
| Adjuvant chemotherapy, n (%) | |
| No | 439 (62.2) |
| Yes | 268 (37.8) |
*
Tumors were classified according to the American Joint Committee on Cancer TNM system.
ASA indicates American Society of Anesthesiologists; AV, anal verge; BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; IQR, interquartile range; NAC, neoadjuvant chemotherapy; NACRT, neoadjuvant chemoradiotherapy; RT, radiotherapy; TNM, tumor-node-metastasis; TNT, total neoadjuvant therapy.